Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

达帕格列嗪 医学 肾脏疾病 蛋白尿 肾功能 安慰剂 内科学 肌酐 泌尿科 糖尿病 内分泌学 2型糖尿病 替代医学 病理
作者
Hiddo J.L. Heerspink,Arihiro Kiyosue,David Collins. Wheeler,Min Lin,Emma Wijkmark,Glenn F. Carlson,Anne‐Kristina Mercier,Magnus Åstrand,Sebastian Ueckert,Peter J. Greasley,Phil Ambery
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10416): 2004-2017 被引量:165
标识
DOI:10.1016/s0140-6736(23)02230-4
摘要

Background In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) decline. We assessed the albuminuria-lowering efficacy and safety of the ERA zibotentan combined with the SGLT2 inhibitor dapagliflozin. Methods ZENITH-CKD was a multicentre, randomised, double-blind, active-controlled clinical trial, done in 170 clinical practice sites in 18 countries. Adults (≥18 to ≤90 years) with an estimated GFR (eGFR) of 20 mL/min per 1·73 m2 or greater and a urinary albumin-to-creatinine ratio (UACR) of 150–5000 mg/g were randomly assigned (2:1:2) to 12 weeks of daily treatment with zibotentan 1·5 mg plus dapagliflozin 10 mg, zibotentan 0·25 mg plus dapagliflozin 10 mg, or dapagliflozin 10 mg plus placebo, as adjunct to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers if tolerated. The primary endpoint was a change from baseline in log-transformed UACR (zibotentan 1·5 mg plus dapagliflozin vs dapagliflozin plus placebo) at week 12. Fluid retention was an event of special interest, defined as an increase in bodyweight of at least 3% (at least 2·5% must have been from total body water) from baseline or an increase of at least 100% in B-type natriuretic peptide (BNP) and either a BNP concentration greater than 200 pg/mL if without atrial fibrillation or BNP greater than 400 pg/mL if with atrial fibrillation. This trial is registered with ClinicalTrials.gov, NCT04724837, and is completed. Findings Between April 28, 2021, and Jan 17, 2023, we assessed 1492 participants for eligibility. For the main analysis, we randomly assigned 449 (30%) participants, 447 (99%) of whom (mean age 62·8 years [SD 12·1], 138 [31%] female, 309 [69%] male, 305 [68%] White, mean eGFR 46·7 mL/min per 1·73 m2 [SD 22·4], and median UACR 565·5 mg/g [IQR 243·0–1212·6]) received treatment with zibotentan 1·5 mg plus dapagliflozin (n=179 [40%]), zibotentan 0·25 mg plus dapagliflozin (n=91 [20%]), or dapagliflozin plus placebo (n=177 [40%]). Zibotentan 1·5 mg plus dapagliflozin and zibotentan 0·25 mg plus dapagliflozin reduced UACR versus dapagliflozin plus placebo throughout the treatment period of the study. At week 12, the difference in UACR versus dapagliflozin plus placebo was –33·7% (90% CI –42·5 to –23·5; p<0·0001) for zibotentan 1·5 mg plus dapagliflozin and –27·0% (90% CI –38·4 to –13·6; p=0·0022) for zibotentan 0·25 mg plus dapagliflozin. Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1·5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0·25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. Interpretation Zibotentan combined with dapagliflozin reduced albuminuria with an acceptable tolerability and safety profile and is an option to reduce chronic kidney disease progression in patients already receiving currently recommended therapy. Funding AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
匆匆发布了新的文献求助10
刚刚
刚刚
刚刚
plddd完成签到,获得积分10
刚刚
小宋完成签到,获得积分0
1秒前
1秒前
itsdeva发布了新的文献求助10
2秒前
gg发布了新的文献求助10
2秒前
2秒前
2秒前
三哥秦发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
ou发布了新的文献求助10
4秒前
zjy发布了新的文献求助10
4秒前
5秒前
5秒前
plddd发布了新的文献求助30
5秒前
森海完成签到,获得积分10
5秒前
6秒前
匆匆发布了新的文献求助10
6秒前
6秒前
7秒前
跳越光子发布了新的文献求助10
7秒前
张贵川完成签到 ,获得积分10
7秒前
霸气的小熊猫完成签到,获得积分20
7秒前
一品真意完成签到,获得积分10
8秒前
小蘑菇的应助被Derek采纳,获得10
8秒前
Lee发布了新的文献求助10
8秒前
April发布了新的文献求助10
9秒前
乐观碧彤发布了新的文献求助10
9秒前
开朗啤酒发布了新的文献求助10
9秒前
冰夜雨发布了新的文献求助10
10秒前
诸沧海发布了新的文献求助10
10秒前
11秒前
酸甜完成签到,获得积分10
11秒前
11秒前
11秒前
高挑的豪完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193729
求助须知:如何正确求助?哪些是违规求助? 9579876
关于积分的说明 21868333
捐赠科研通 7793519
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560856
邀请新用户注册赠送积分活动 2484216